Abstract CPC-148 Table 3
Adalimumab
Autoimmune hepatitis 25% (1/4)
Asthenia and mood changes 25% (1/4)
Psoriatic arthritis 25% (1/4)
Pharyngitis and candidiasis 25% (1/4)
Infliximab
Acute infusion reactions 75% (3/4)
Psoriatic arthropathy 25% (1/4)